Is the news that Dali Rayson will be launched in China true?

In recent years, with the accelerated pace of life and increased stress, the number of patients with insomnia has increased year by year, and more and more treatment drugs have emerged. Daridorexant, as a new type of sleep regulating drug, has received widespread attention around the world. So, is the news about whether Dali Rayson will be launched in China true?

According to the latest news, the original drug of Dalilayson (Dalilayson hydrochloride tablets, trade name QUVIVIQ/QUVIVIQ) has been approved by the China National Medical Products Administration (NMPA) and will be launched in the Chinese market. This news indicates that DaliRasen’s registration approval in China has been approved, which means that this drug will soon become a treatment option for Chinese patients with insomnia.

DaliRasen is a new type ofOrexin receptor antagonist, which mainly helps improve the sleep quality of patients with insomnia by inhibiting Orexin receptors. Different from traditional benzodiazepines, it not only has lower side effects, but can also effectively regulate the patient's sleep structure, improve the depth and duration of sleep, thereby helping insomnia patients return to their normal routine.

On June 20, 2025, the news that the original drug of DaliRasen was successfully approved for marketing marked a milestone for the drug to enter the Chinese market. This move undoubtedly provides a new treatment option for the vast number of insomnia patients, especially when faced with the problem of side effects of traditional hypnotic drugs, the advantages of DaliRasen are becoming more and more obvious.

Despite this, as DaliRasen has just been launched in China, the price of the drug and related medical insurance policies are still not fully clear. Patients can obtain relevant drugs through formal channels according to their own needs and understand the specific costs of treatment.

Reference materials:https://www.quviviq.com/